



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

\*CORRESPONDENCE  
Wenqing Jia,  
✉ wenqingjia0312@163.com  
Yukui Ma,  
✉ yaoliduli@163.com

RECEIVED 19 December 2024  
ACCEPTED 20 December 2024  
PUBLISHED 06 January 2025

CITATION  
Li G, Xian S, Cheng X, Hou Y, Jia W and Ma Y  
(2025) Corrigendum: Efficacy of Oroxylin A in  
ameliorating renal fibrosis with emphasis on  
Sirt1 activation and TGF- $\beta$ /  
Smad3 pathway modulation.  
*Front. Pharmacol.* 15:1548193.  
doi: 10.3389/fphar.2024.1548193

COPYRIGHT  
© 2025 Li, Xian, Cheng, Hou, Jia and Ma. This is  
an open-access article distributed under the  
terms of the [Creative Commons Attribution  
License \(CC BY\)](#). The use, distribution or  
reproduction in other forums is permitted,  
provided the original author(s) and the  
copyright owner(s) are credited and that the  
original publication in this journal is cited, in  
accordance with accepted academic practice.  
No use, distribution or reproduction is  
permitted which does not comply with these  
terms.

# Corrigendum: Efficacy of Oroxylin A in ameliorating renal fibrosis with emphasis on Sirt1 activation and TGF- $\beta$ /Smad3 pathway modulation

Guangzhuang Li<sup>1</sup>, Sentao Xian<sup>2</sup>, Xianchao Cheng<sup>3</sup>, Yunhua Hou<sup>1</sup>,  
Wenqing Jia<sup>2\*</sup> and Yukui Ma<sup>2\*</sup>

<sup>1</sup>School of Bioengineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, Shandong, China, <sup>2</sup>School of Chemistry and Chemical Engineering, Qilu Normal University, Jinan, China, <sup>3</sup>Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, China

## KEYWORDS

Oroxylin A, chronic kidney disease, renal fibrosis, Sirt1, molecular docking

## A Corrigendum on Efficacy of Oroxylin A in ameliorating renal fibrosis with emphasis on Sirt1 activation and TGF- $\beta$ /Smad3 pathway modulation

by Li G, Xian S, Cheng X, Hou Y, Jia W and Ma Y (2024). *Front. Pharmacol.* 15:1499012. doi: 10.3389/fphar.2024.1499012

In the published article, there was an error in **Affiliation 1**. Instead of “School of Bioengineering, Shandong Academy of Sciences, Qilu University of Technology, Jinan, China,” it should be “School of Bioengineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, Shandong, China.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.